Mesoblast (OTC: MEOBF) CMO details initial option and share holdings

Rhea-AI Filing Summary

Mesoblast Ltd director and Chief Medical Officer Eric Allen Rose has filed an initial Form 3 detailing his equity interests in the company. He directly holds 6,034,554 Ordinary Shares and an additional 714,720 Ordinary Shares, which are represented by American Depositary Shares.

He also reports multiple option awards over Ordinary Shares, including 820,000 underlying shares at an exercise price of $2.46 per share expiring in 2032, and other grants at exercise prices of $0.35, $0.36, $0.97, $1.01, and $1.81 with expirations between 2026 and 2031. Several recent option grants vest only if Mr. Rose achieves specified milestones.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ROSE ERIC ALLEN

(Last) (First) (Middle)

LEVEL 38

55 COLLINS STREET

(Street)

MELBOURNE, VICTORIA 3000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
MESOBLAST LTD [ MESO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer,Director

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	6,034,554	D
Ordinary Shares(1)	714,720	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	11/17/2020	11/17/2026	Ordinary Shares	33,333	$1.81	D
Option (right to buy)	11/17/2021	11/17/2026	Ordinary Shares	33,333	$1.81	D
Option (right to buy)	11/17/2022	11/17/2026	Ordinary Shares	33,334	$1.81	D
Option (right to buy)	10/17/2023	10/16/2029	Ordinary Shares	716,667	$1.01	D
Option (right to buy)	04/12/2024	10/11/2030	Ordinary Shares	406,922	$0.36	D
Option (right to buy)	07/12/2024	10/11/2030	Ordinary Shares	406,922	$0.36	D
Option (right to buy)	10/12/2024	10/11/2030	Ordinary Shares	406,921	$0.36	D
Option (right to buy)	10/16/2024	10/15/2030	Ordinary Shares	148,000	$0.35	D
Option (right to buy)	10/17/2024	10/16/2029	Ordinary Shares	716,667	$1.01	D
Option (right to buy)	02/27/2025	08/26/2031	Ordinary Shares	145,562	$0.97	D
Option (right to buy)	05/27/2025	08/26/2031	Ordinary Shares	145,562	$0.97	D
Option (right to buy)	08/27/2025	08/26/2031	Ordinary Shares	460,896	$0.97	D
Option (right to buy)	10/17/2025	10/16/2029	Ordinary Shares	716,666	$1.01	D
Option (right to buy)	(2)	10/15/2030	Ordinary Shares	592,000	$0.35	D
Option (right to buy)	(3)	08/26/2031	Ordinary Shares	630,666	$0.97	D
Option (right to buy)	(4)	08/25/2032	Ordinary Shares	820,000	$2.46	D

Explanation of Responses:

1. Such Ordinary Shares are represented by American Depositary Shares.

2. Granted on October 16, 2023. Vesting is dependent on Mr. Rose achieving certain milestones.

3. Granted on August 27, 2024. Vesting is dependent on Mr. Rose achieving certain milestones.

4. Granted on August 26, 2025. Vesting is dependent on Mr. Rose achieving certain milestones.

Remarks:

1. All exercise prices are in Australian dollars.

	/s/ Eric Allen Rose	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Mesoblast (MEOBF) Form 3 for Eric Allen Rose show?

The Form 3 shows that Eric Allen Rose, Mesoblast’s Chief Medical Officer and director, has reported his existing holdings of Ordinary Shares and multiple option awards. It is an initial ownership statement, not a record of new purchases or sales.

How many Mesoblast Ordinary Shares does Eric Allen Rose directly hold?

Eric Allen Rose reports direct ownership of 6,034,554 Mesoblast Ordinary Shares plus a separate holding of 714,720 Ordinary Shares. According to the filing, these Ordinary Shares are represented by American Depositary Shares, which facilitate trading for non‑U.S. investors.

What stock options are reported for Eric Allen Rose in the Mesoblast Form 3?

The filing lists several option grants over Mesoblast Ordinary Shares, including 820,000 underlying shares at a $2.46 exercise price expiring in 2032 and additional options at $0.35, $0.36, $0.97, $1.01, and $1.81 with expirations between 2026 and 2031.

Do Eric Allen Rose’s Mesoblast options depend on performance milestones?

Yes. The Form 3 footnotes state that option grants dated October 16, 2023, August 27, 2024, and August 26, 2025 vest only if Mr. Rose achieves specified milestones. This means some options become exercisable only when those conditions are satisfied.

Does this Mesoblast Form 3 indicate recent buying or selling by Eric Allen Rose?

No transactions are classified as buys or sells in the filing. All entries are reported as holdings with unknown transaction codes, so the document functions as a snapshot of Mr. Rose’s current share and option positions rather than recent trading activity.

How long do Eric Allen Rose’s Mesoblast options remain exercisable?

The option expirations disclosed range from 2026 through 2032. For example, options at a $1.81 exercise price expire in 2026, while the grant with an exercise price of $2.46 per share expires on August 25, 2032, if vesting conditions are met.